MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: -11.0%
1M: -13.4%
3M: -6.8%
YTD: -27.1%
1Y: +69.6%
3Y: +75.0%
$28.43
+2.40 (+9.22%)
After Hours: $27.11 (-1.32, -4.66%)
Weekly Expected Move ±8.2%
$23
$25
$27
$30
$32
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$8.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range12.59-47.65
Volume4,293,852
Avg Volume1,202,626
Beta0.48
Dividend—
Analyst Ratings
Company Info
CEOJon Congleton
Employees51
SectorHealthcare
IndustryBiotechnology
IPO Date2023-02-10
Websitemineralystx.com
150 N. Radnor Chester Rd.
Radnor, PA 19087
US
Radnor, PA 19087
US
888-378-6240
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Latest News
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA
Mineralys (MLYS) Q1 2026 Earnings Transcript
Earnings Scheduled For May 6, 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rodman David Malcom | M-Exempt | 417 | $15.44 | 2026-05-18 |
| Rodman David Malcom | S-Sale | 417 | $27.55 | 2026-05-18 |
| Rodman David Malcom | M-Exempt | 417 | $15.44 | 2026-05-18 |
| Rodman David Malcom | M-Exempt | 3,541 | $10.20 | 2026-05-13 |
| Rodman David Malcom | M-Exempt | 4,166 | $14.25 | 2026-05-13 |